Aging impairs dendritic cell (DC) function through defective migration and attenuated Toll-like receptor (TLR) signaling, yet the underlying cause of the signaling defect remains incompletely defined. We hypothesize that age‑dependent alterations in plasma membrane cholesterol content disrupt the assembly of MyD88‑dependent signaling platforms, converting the normally digital NF‑κB response into a noisy, subthreshold signal that fails to drive maturation cytokines and promotes PD‑L1 upregulation. Restoring membrane lipid order with cyclodextrin‑mediated cholesterol depletion will re‑establish reliable MyD88 oligomerization, revive digital NF‑κB dynamics, and synergize with PD‑L1 blockade to rescue DC‑mediated T cell activation in aged hosts.

Mechanistic rationale TLR4/MyD88 signaling relies on the formation of transient, cholesterol‑rich lipid rafts where MyD88 dimerizes and recruits IRAKs to ignite the Myddosome 3. Single‑cell imaging shows that digital NF‑κB pulses correlate with stable Myddosome formation; stochastic loss of this platform yields graded, insufficient NF‑κB activity 3. Aging is associated with increased membrane cholesterol and altered phospholipid composition in myeloid cells, which can rigidify rafts and impede the rapid, reversible protein‑protein interactions required for signal transduction. Consequently, aged DCs exhibit blunted IκBα degradation and p65 phosphorylation despite TLR ligation, leading to weak IL‑6/TNF production and a compensatory rise in basal type I IFN that further desensitizes TLR responses 4. The chronic low‑grade IFN milieu also drives PD‑L1 expression via STAT1 signaling, creating an inhibitory brake on CD8+ T cells.

We propose that acute, moderate cholesterol depletion using methyl‑β‑cyclodextrin (MβCD) will restore raft fluidity without causing cytotoxicity, permitting proper MyD88 platform assembly. This should convert the attenuated, analog NF‑κB response back to a digital mode, boosting downstream cytokine production and costimulatory molecule expression. Simultaneous PD‑L1 blockade will remove the inhibitory checkpoint, allowing the reinvigorated DCs to effectively prime naïve T cells.

Experimental plan (testable and falsifiable)

1. In vitro: Isolate bone‑marrow derived DCs (BMDCs) from young (2‑3 mo) and aged (18‑24 mo) mice. Treat cells with 0.5 mM MβCD for 30 min, wash, then stimulate with a MyD88‑biased TLR agonist (e.g., MPLA) ± anti‑PD‑L1 antibody. Measure:
   • NF‑κB dynamics using live‑cell p65‑GFP imaging (pulse frequency and amplitude).
   • IL‑6 and TNF secretion by ELISA.
   • Surface CD80/CD86 and PD‑L1 flow cytometry.
   • Cholesterol levels via filipin staining. Prediction: MβCD treatment will increase NF‑κB pulse frequency and IL‑6/TNF in aged DCs to young‑cell levels; PD‑L1 blockade will further reduce PD‑L1 surface expression. Lack of rescue would falsify the hypothesis.
2. In vivo: Administer aged mice with subcutaneous MPLA nanoparticles pre‑loaded with MβCD (or co‑inject free MβCD) plus systemic anti‑PD‑L1 prior to immunization with a model antigen (OVA). Assess:
   • DC migration to draining lymph nodes (CFSE‑labelled DCs).
   • Antigen presentation efficacy (OVA‑specific CD4+ T cell proliferation).
   • IFN‑γ producing CD8+ T cells (ELISPOT).
   • Tumor growth or infection clearance as functional readouts. Prediction: Combined treatment will enhance DC migration, boost cytokine milieu, and improve T cell responses compared with either intervention alone. Failure to observe additive benefits would challenge the hypothesis.

Broader implications If validated, this work links membrane biophysics to intracellular signaling fidelity in immunosenescence, suggesting that lipid‑targeting agents could be repurposed to improve vaccine efficacy in the elderly. It also provides a mechanistic bridge between the two observed defects—impaired migration (potentially via altered chemokine receptor raft localization) and TLR hyporesponsiveness—offering a unified therapeutic angle.